[Skip to Content]
[Skip to Content Landing]
February 2018

Evidence-Based Management of Patent Foramen Ovale in Patients With Ischemic Stroke

Author Affiliations
  • 1Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York
  • 2Division of Stroke and Neurocritical Care, Department of Neurology, Weill Cornell Medical College, New York, New York
  • 3Associate Editor, JAMA Neurology
JAMA Neurol. 2018;75(2):147-148. doi:10.1001/jamaneurol.2017.3982

Clinicians have long suspected that a patent foramen ovale (PFO) or an atrial septal aneurysm can be a nidus or conduit for thromboembolism and, therefore, a risk factor for stroke. Epidemiological studies have generally found an association between PFO and ischemic stroke.1 As a result, investigators have published results from 5 randomized clinical trials of percutaneous PFO closure in patients with ischemic stroke since 2012.1-5